Clinical Trial Update: Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation

View source ↗

Summary

An observational program evaluating Zemplar (paricalcitol) for secondary hyperparathyroidism in end-stage renal disease patients on hemodialysis in Russia; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Secondary Hyperparathyroidism | Status: COMPLETED | Results posted: 2014-02-28